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We studied the 2-year death rate of 246 adults dis-
charged from hospital after experiencing acute West Nile
Virus infection in Israel during 2000. The age- and sex-
adjusted death rates were significantly higher than in the
general population. This excess was greater for men.
Significant adverse prognostic factors were age, male sex,
diabetes mellitus, and dementia. 
W
est Nile virus (WNV) was first isolated in 1937 (1,2)
and has since been found in Europe, Africa, Asia, and
North America (1). Human WNV infection was first docu-
mented in Israel in 1951 (3). Several outbreaks occurred
during the 1950s and during the following 40 years, but
mainly sporadic cases occurred (4). In 2000, an epidemic of
428 serologically confirmed cases led to 42 deaths during
the acute phase of the illness (5). Little has been reported in
the literature on the long-term sequelae of WNV infection.
In 1953, 70 patients 18–20 years of age were followed up
for <11 months, and no serious sequelae or deaths were
observed (6). Although 12% of the patients in the New York
outbreak in 1999 died during the acute phase of the illness,
no deaths occurred among the 35 patients followed up for 1
year after hospitalization (7). The aim of the present study
was to determine whether infection with WNV has long-
term effects on death rates and to evaluate variables such as
age, sex, symptoms and signs, and coexisting conditions as
potential prognostic factors.
The Study
Between July 1 and November 30, 2000, 428 patients
with serologic diagnoses of WNV infection were reported
to the Ministry of Health (MOH) Department of
Epidemiology. Diagnosis of WNV infection was made on
the basis of symptoms, signs, and laboratory confirmation
of the presence of immunoglobulin M (IgM) antibodies.
All serologic tests were performed in the MOH’s Central
Virology Laboratory by using an IgM-capture enzyme-
linked immunosorbent assay in serum or cerebrospinal
fluid samples of patients (8). At the time of the epidemic,
this was the working definition of a case of WNV infec-
tion. While WNV IgM antibodies can persist >1 year (9),
a seroepidemiologic study in a healthy population in Israel
at the time of the outbreak, using the same laboratory
methods, found only 1.2% had IgM antibodies (M.Y.
Chowers et al., unpub. data). Thus, few, if any, false-posi-
tive results would be expected.
The study population was limited to the 326 hospital-
ized patients. After excluding 34 patients <20 years of age
and the 46 patients who died during hospitalization or
within 1 week of discharge, 246 survivors were eligible for
follow-up. Demographic data on the cases and date of
onset of the disease were obtained from the Department of
Epidemiology. The mean ages of the patients were 57.8
years for men and 62.8 years for women. Clinical data on
symptoms and coexisting conditions were obtained from
the hospital discharge letters. Of eligible survivors, 48.3%
had diagnoses of encephalitis or meningoencephalitis,
13.5% had a diagnosis of meningitis, 28.2% had fever,
rash, or both, and the other 10% of the survivors had other
clinical symptoms.
The patients were monitored to determine whether any
deaths occurred from date of hospital discharge until
November 30, 2002. Deaths were determined by matching
the identity numbers of the case-patients with the data in
the national population registry maintained by the Ministry
of Interior. We were able to confirm all deaths in the cohort
during this period. By November 30, 2002, after an aver-
age follow-up period of 24 months (median 26 months,
range 1–29 months), 30 of 246 patients had died.
Death certificates were obtained for all case-patients,
and all causes of death were recorded and coded by using
the International Classification of Disease, Ninth Revision.
The coding was reviewed independently by another coder,
and the underlying cause of death was determined by using
World Health Organization criteria. 
Bivariate comparisons between characteristics of the
patients who died and the survivors were carried out by
using the χ2 and t tests. Kaplan-Meier survival curves were
constructed for all patients and for men and women sepa-
rately, and the difference between men and women was
compared by using the log-rank test. The age-standardized
mortality ratios (SMRs) were computed by using the per-
son-time method with the PAMCOMP program (Institute
of Epidemiology and Social Medicine, University of
Muenster, Muenster, Germany) (10). SMRs were calculat-
ed by dividing the observed number of deaths by the
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from the reported onset of the disease until either death or
November, 30, 2002, whichever occurred first. The
expected number of deaths in the study cohort was calcu-
lated by multiplying person-months at risk by the national
death rates in 1997 (the last year for which detailed pub-
lished data are available) for the same age and sex cate-
gories. Exact 95% confidence intervals (CIs) and p values
were calculated by using the Poisson distribution.
Attributable risk was computed by the formula (SMR-
1)/SMR. Prognostic factors were evaluated by using Cox
proportional hazards regression analysis to estimate
adjusted rate ratios while adjusting for other potential
determinants of death. The hazard rate ratio (RR) is
defined as the ratio of the mortality rate in the group of
patients with a given study factor to the rate in those with-
out the factor. We calculated 95% CIs for each adjusted
RR. The SAS package version 8.2 (SAS, Cary, NC, USA)
was used for all calculations other than the SMRs. 
The Kaplan-Meier survival curves are shown for the
total cohort and for men and women separately (Figures 1
and 2). Overall, after 1 year, 7.7% had died and after 2
years, 12.2%. After 1 year the death rate was 6.4% for
women compared with 9.1% for men (p = 0.025), and after
2 years it was 10.4% for women and 14.1% for men (p =
0. 021). 
Age-adjusted SMRs, both sex-specific and sex-adjust-
ed, at 6 months, 1 year, and the end of the follow-up, are
shown in Table 1. The overall SMR at 1 year was nearly
2.5 times higher than expected (SMR = 2.49, 95% CI
1.50–3.89). Among men, the death rate was >3 times
higher than expected, whereas among women the death
rate was less than twice as high and not significant. The
excess risk at the end of the second year was lower and
not significant. Overall, in 50% of the deaths the underly-
ing cause was ascribed to cardiovascular disease. In only
20% was WNV infection given as the underlying cause of
death, although this result is clearly influenced by coding
practices.
In the Cox regression analyses for evaluating demo-
graphic factors and the symptoms and signs as prognostic
factors, while simultaneously controlling for each, only
age, and especially the oldest age group tested (>85 years),
was a significant adverse prognostic factor (data not
shown). Possible interactions between the symptoms and
signs with age and sex were not significant. A second Cox
regression analysis for evaluating coexisting conditions as
prognostic factors is shown in Table 2. After age, sex, and
the other coexisting conditions were controlled for, only
diabetes mellitus and dementia remained as significant,
independent predictors of death (RR = 2.74 and 2.94 for
diabetes mellitus and dementia, respectively). Again, inter-
action effects were not significant.
Conclusions
In this study, excess deaths occurred among survivors
compared with the general population. This excess
appeared to occur mainly in the first year after the acute ill-
ness and was more prominent among men than women.
Older age, and especially the oldest age group tested (>85
years), diabetes mellitus, and dementia were other signifi-
cant independent predictors of death. 
To demonstrate the magnitude of this excess risk, we
compared these findings with an Israeli study of deaths
within 1 year after hospital discharge among patients with
acute myocardial infarction of whom ≈30% had diabetes
(S. Bachar, Acute Coronary Syndrome in Israel 2000
study, unpub. data). After age and sex were controlled for,
the death rate within 1 year for WNV-infected patients in
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Figure 1. Kaplan-Meier survival curves for 2-year mortality follow-
up of 246 patients discharged from hospital after West Nile virus
infection during the epidemic in Israel in 2000. *Survival after 1
year; **survival after 2 years; CI, confidence interval.
Figure 2. Kaplan-Meier survival curves for 2-year mortality follow-
up of 246 patients discharged from hospital after West Nile Virus
infection during the epidemic in Israel in 2000, by sex. *Survival
after 1 year; **survival after 2 years; ***relative risk (RR) for
women compared with men, adjusted for age, diabetes, ischemic
heart disease, immunodeficiency, cerebrovascular disease, hyper-
tension, and dementia.the present study was similar to that of patients after
myocardial infarction (7.7% vs. 9.5%, p = 0.881 ). This
finding indicates that the 1-year postdischarge death risk in
the WNV-infected patients is of a similar magnitude to that
of patients with a severe, acute, noninfectious illness.
The main negative prognostic factors in the present
study were older age, male sex, diabetes mellitus, and
dementia. Similar associations with deaths in the acute
phase of the illness have been observed for age (5,11) and
diabetes mellitus (5). Thus older age and possibly diabetes
mellitus influence both acute-phase and long-term mortal-
ity rates. Why long-term mortality rates, not related to pre-
existing illnesses or age, are higher in men than in women
is unknown. In several studies of clinical WNV infection,
men appeared to have a higher incidence of disease, but
this difference has not been observed in Israel (5). 
Survivors of herpes simplex encephalitis have a shorter
life expectancy (12,13), and to a lesser extent, so have
patients with other viral encephalitides (13). Some of these
excess deaths could be attributed to severe neurologic
impairment and instability, while other deaths were unre-
lated to the infection. 
The reasons for the increased long-term death rate in
survivors of acute WNV infection are not clear. The clini-
cal features described in WNV encephalitis have been
described as typical for arboviral encephalitides (1).
Severe neurologic sequelae have been described in sur-
vivors of invasive WNV infection, and a substantial num-
ber of patients do not regain their baseline function (8).
This deficit could contribute to an increase in deaths.
In this epidemic in Israel, 2 clades of WNV were isolat-
ed (8,14). One was closely related to the 1999 New York
isolate and the other to a 1999 Russian isolate and a 1997
Romanian isolate (14). The outbreak was characterized by
relatively high case-fatality rates among hospitalized
patients; 14% of the patients died during the acute phase
(5). This rate is similar to that observed in the New York
outbreak (15). No evidence suggests that the virus in Israel
was any different in virulence. 
The results of this study on the potential long-term
impact of WNV infection are relevant for hospitalized
patients. They may have been more susceptible to clinical
WNV infection. The significant excess death rate indicates
that the combined case-fatality rate in all hospitalized
patients in the acute and convalescent phases could be
>10%, and in patients >65, >30% (5). Thus, such patients
require long-term monitoring and support. Possible sex
differences in death rates require further investigation. 
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